Exablate for LIFU Neuromodulation in Patients With Opioid Use Disorder (OUD) and/or Other Substance Use Disorders (SUDs)
NCT04197921
This study is recruiting at 3 US sites in 3 states, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this clinical trial is to investigate Low Intensity Focused Ultrasound (LIFU) using the Exablate® Model 4000 Type 2.0/2.1 as an adjunctive neuromodulatory treatment for OUD (Opioid Use Disorder) and/or other Substance Use Disorders (SUDs) by assessing its safety and tolerability in subjects with OUD.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Opioid-use Disorder
- Substance Use Disorders
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Not applicable
- Ages
- 18 to 60 years
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- InSightec
- Last updated on ClinicalTrials.gov
- June 26, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Maryland · 1
- University of Maryland, Baltimore · Baltimore, MD
New York · 1
- Weill Cornell Medicine · New York, NY
West Virginia · 1
- West Virginia University: Rockefeller Neuroscience Institute · Morgantown, WV
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.